Loading
A phase 2 trial of Tislelizumab, Capecitabine, Fluorouracil (5-FU) and Oxaliplatin in gastric & gastro-oesophageal junction cancer and oesophageal cancer, run by BeOne Medicines, now recruiting.
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States is a phase 2 interventional study registered as NCT07554521 by BeOne Medicines, with 30 participants planned, started 2026-04-30 and due to reach its primary completion in 2031-12-31. Interventions recorded: Tislelizumab, Capecitabine, 5-fluorouracil (5-FU), Oxaliplatin and Leucovorin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Oxaliplatin, Fluorouracil (5-FU), Capecitabine, Oesophageal cancer and the tag pipeline.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Tislelizumab, Oxaliplatin, Capecitabine, Immune checkpoint inhibitors and the tag pipeline.
Shares Tislelizumab, Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Oxaliplatin, Fluorouracil (5-FU), Oesophageal cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Oxaliplatin, Fluorouracil (5-FU), Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/